Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Approved, Seladelpar Can Provide an Important Treatment Option for People Living With the Rare Liver Disease in the European Economic Area – ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

What comes to mind when you think about sportswear? Is it the smoothness of running shoes or the convenience of your favourite gym shorts? Or maybe those famous logos let you know at a glance which ...

Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...

Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our ...

NTT Research, Inc., a division of NTT (TYO:9432), and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced the publication of research showing an application of ...

A minority of patients with PSC had cirrhosis (approximately 10%) and none of them had decompensated cirrhosis. A large majority of patients with PSC (more than 90%) were treated with ursodeoxycholic ...

Therefore, the patient was diagnosed with IRH, and the PD-1 inhibitor tislelizumab was interrupted. The patient continued to receive ursodeoxycholic acid (UDCA) and was administered intravenous pulse ...